No increase in rates of early-onset neonatal sepsis by non-group B Streptococcus or ampicillin-resistant organisms

Am J Obstet Gynecol. 2001 Oct;185(4):854-8. doi: 10.1067/mob.2001.117354.


Objective: We assessed the impact of a risk-based approach to group B Streptococcus (GBS) prophylaxis on the rates of early-onset neonatal sepsis (EONS).

Study design: A retrospective cohort study of neonates born at a tertiary-care hospital from 1990 to 1996 was performed. Cases of EONS were identified among neonates born in a period without GBS prophylaxis (1990-1992) and compared with those born in a period with GBS prophylaxis (1993-1996). The antibiotic susceptibility data on each organism isolated in the blood culture were obtained.

Results: In the period without prophylaxis, 99 cases of EONS were identified among 25,934 neonates for a rate of 3.8 per 1000 births. In the period with prophylaxis, 90 cases of EONS occurred among 34,262 neonates for a rate of 2.6 per 1000. The rate of GBS-EONS significantly decreased between the 2 periods (from 1.9 to 1.1, P =.01). There was a trend toward a decrease in the rate of EONS caused by non-GBS gram-positive organisms (from 1.2 to 0.7, P =.06). There was no significant increase in the rate of EONS caused by gram-negative or ampicillin-resistant organisms.

Conclusions: A risk-based approach to GBS prophylaxis reduced the incidence of GBS-EONS at a tertiary-care hospital. This decrease was not accompanied by an increase in the incidence of EONS by non-GBS or ampicillin-resistant organisms.

Publication types

  • Comparative Study

MeSH terms

  • Age of Onset
  • Ampicillin / administration & dosage*
  • Ampicillin Resistance
  • Bacteremia / epidemiology*
  • Bacteremia / prevention & control
  • Case-Control Studies
  • Cohort Studies
  • Female
  • Humans
  • Infant, Newborn
  • Infant, Newborn, Diseases / epidemiology
  • Infant, Newborn, Diseases / prevention & control
  • Microbial Sensitivity Tests
  • Pregnancy
  • Pregnancy Trimester, Third
  • Prevalence
  • Probability
  • Reference Values
  • Retrospective Studies
  • Risk Assessment
  • Streptococcal Infections / drug therapy
  • Streptococcal Infections / epidemiology*
  • Streptococcus agalactiae / drug effects*


  • Ampicillin